Development and Validation of Highly Sensitive LC–ESI-MS/MS Method for Bortezomib and Its Applications for Plasma Levels and Drug Content of Branded and Generic Formulations in India

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma

(2019) Laura Rosiñol et al.   BLOOD

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

LC–MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients

(2016) Chang Shu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice

(2015) Li Zhang et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS

(2013) Irina Andriamanana et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development and validation of a LC–MS/MS method for homocysteine thiolactone in plasma and evaluation of its stability in plasma samples

(2013) Beauty Arora et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile

(2011) Stephen R. Byrn et al.   AAPS PHARMSCITECH

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

(2008) P. Moreau et al.   HAEMATOLOGICA